Angiopoietin-TIE2 Signaling Pathway: Mechanisms of Vascular Homeostasis, Permeability Regulation, and Pathological Vascular Remodeling

The Angiopoietin-TIE2 signaling pathway is an important axis regulating vascular maturation, endothelial barrier stability, vascular inflammatory responses, and pathological vascular remodeling. This pathway is centered on the TIE2/TEK receptor and is jointly controlled by related regulatory factors such as ANGPT1, ANGPT2, TIE1, VE-PTP, and VEGF. ANGPT1 generally maintains vascular quiescence and barrier integrity, whereas ANGPT2 promotes vascular destabilization, increased permeability, and abnormal remodeling under hypoxic, inflammatory, tumor-related, and tissue injury conditions.

Keywords: Angiopoietin; TIE2; TEK; ANGPT1; ANGPT2; TIE1; angiogenesis; endothelial barrier; vascular permeability; pericytes; VEGF; tumor vessels; inflammatory microenvironment; endothelial homeostasis

1、Basic Composition of the Angiopoietin-TIE2 Pathway

1.1 TIE2/TEK Receptor

(1) Receptor properties

TIE2, also known as TEK, is a receptor tyrosine kinase mainly expressed in vascular endothelial cells. Its extracellular region binds Angiopoietin family ligands, while its intracellular kinase domain initiates downstream signaling after receptor clustering and phosphorylation. TIE2 not only participates in angiogenesis but also maintains low permeability, low inflammation, and anti-apoptotic status in mature blood vessels.

(2) Expressing cells

TIE2 is most typically expressed in vascular endothelial cells. Some hematopoietic-derived cells, monocyte/macrophage subsets, and TIE2-expressing cells in the tumor microenvironment can also participate in this pathway. In scientific interpretation, endothelial TIE2 signaling should be distinguished from TIE2-expressing macrophage-related effects, because their meanings in tumor vessels, inflammatory tissues, and hypoxic microenvironments are not the same.

(3) Functional positioning

After TIE2 activation, it usually promotes endothelial cell survival, stabilization of cell junctions, and maintenance of vascular quiescence. When TIE2 signaling is weakened, endothelial cells are more prone to inflammatory activation, junctional loosening, vascular leakage, and abnormal vascular sprouting.

1.2 Angiopoietin Family Ligands

(1) ANGPT1

ANGPT1 is mainly produced by pericytes, smooth muscle cells, stromal cells, and some tissue-supporting cells. Its typical role is to activate TIE2, promote vascular maturation, stabilize endothelial junctions, recruit pericytes, and maintain a low-permeability vascular state. ANGPT1 is often regarded as a vascular homeostatic and vasoprotective ligand.

(2) ANGPT2

ANGPT2 is mainly stored in endothelial Weibel-Palade bodies and is rapidly released under hypoxia, VEGF stimulation, inflammatory cytokine stimulation, vascular injury, and tumor microenvironmental conditions. ANGPT2 often acts as a competitive regulator of the ANGPT1-TIE2 axis, making vessels more responsive to VEGF, inflammatory signals, and changes in shear stress.

(3) ANGPT4 and related members

Human ANGPT4 can also be related to TIE2 signaling, but it is generally studied less frequently than ANGPT1 and ANGPT2. The species correspondence and functional interpretation of mouse Angpt3 and human ANGPT4 should be handled carefully and should not be simply equated.

1.3 TIE1, VE-PTP, and VEGF Background

(1) TIE1

TIE1 is a TIE2-related receptor tyrosine kinase. It usually does not function independently as a typical ligand-binding receptor, but regulates TIE2 signaling intensity, receptor complex status, and endothelial cell responses to inflammatory stimuli. TIE1 cleavage or altered expression can affect the functional outcomes of ANGPT1/ANGPT2 on TIE2.

(2) VE-PTP

VE-PTP can dephosphorylate TIE2 and reduce TIE2 activation. VE-PTP inhibition can enhance TIE2 phosphorylation and is important in studies of vascular stabilization, barrier protection, and inflammatory vascular leakage.

(3) VEGF background

The function of ANGPT2 is highly dependent on the VEGF background. When VEGF is sufficient, ANGPT2 can promote vascular sprouting, vascular dilation, and neovessel formation. When VEGF is insufficient, ANGPT2 is more likely to cause vascular regression, endothelial instability, or vessel withdrawal. Therefore, increased ANGPT2 cannot be interpreted alone as enhanced angiogenesis.

Table 1 Core Components and Functional Positioning of the Angiopoietin-TIE2 Pathway

Component	Molecular property	Main source or expression	Core function
TIE2/TEK	Receptor tyrosine kinase	Vascular endothelial cells; some TIE2-expressing immune cells	Maintains vascular stability, endothelial survival, and barrier integrity
ANGPT1	TIE2-activating ligand	Pericytes, smooth muscle cells, stromal cells	Promotes TIE2 activation, vascular maturation, and low-permeability state
ANGPT2	TIE2-regulatory ligand	Endothelial Weibel-Palade bodies	Promotes vascular destabilization, inflammatory response, and pathological remodeling
ANGPT4	Angiopoietin family member	Multiple tissue cell types	Participates in TIE2-related regulation depending on tissue context
TIE1	TIE2 co-regulatory receptor	Vascular endothelial cells	Regulates the TIE2 complex and endothelial inflammatory response
VE-PTP	TIE2 dephosphorylation regulator	Endothelial cells	Inhibits TIE2 phosphorylation and affects vascular barrier stability
VEGF	Angiogenic factor	Hypoxic tissues, tumor cells, inflammatory cells, etc.	Determines whether ANGPT2 promotes angiogenesis or vascular regression

2、ANGPT1-TIE2-Mediated Vascular Stabilization Signaling

2.1 TIE2 Phosphorylation and Receptor Clustering

(1) Receptor activation

ANGPT1 usually binds TIE2 in a multimeric form, causing receptor clustering and tyrosine phosphorylation. After TIE2 phosphorylation, downstream adaptor proteins can be recruited, activating PI3K-AKT, ERK, FOXO1, and endothelial junction-related regulatory signals.

(2) Spatial features

ANGPT1-TIE2 signaling is often associated with cell-cell junction regions. When TIE2 is activated at endothelial junctions, it is more likely to enhance the vascular barrier and endothelial quiescence. Under different extracellular matrix conditions, cell densities, or shear stress environments, TIE2 signal outputs may differ.

(3) Experimental interpretation

Increased total TIE2 protein does not equal pathway activation. Pathway activation should be evaluated mainly by p-TIE2, p-AKT, changes in FOXO1 nuclear localization, VE-cadherin junction status, and endothelial permeability changes.

2.2 PI3K-AKT and Endothelial Survival

(1) AKT activation

After ANGPT1 activates TIE2, it can promote endothelial cell survival through the PI3K-AKT pathway and reduce apoptosis and stress injury. AKT can also affect eNOS activity, NO production, and vascular relaxation regulation.

(2) Anti-apoptotic effect

AKT signaling can inhibit some pro-apoptotic molecules and enhance endothelial cell survival under hypoxia, inflammatory cytokines, or mechanical stress. This effect is an important basis for the vasoprotective function of ANGPT1.

(3) Significance in vascular homeostasis

In mature blood vessels, the ANGPT1-TIE2-AKT axis helps maintain a low-inflammatory, low-permeability, and anti-apoptotic endothelial state. If this axis is impaired, vessels are more likely to undergo inflammatory activation, leakage, and abnormal remodeling.

2.3 FOXO1 and ANGPT2 Feedback

(1) FOXO1 regulation

FOXO1 is an important transcription factor regulating ANGPT2 expression in endothelial cells. ANGPT1-TIE2-AKT signaling can inhibit FOXO1 nuclear localization, thereby reducing ANGPT2 transcription.

(2) Negative feedback relationship

When TIE2-AKT signaling is strong, ANGPT2 expression tends to be suppressed and vessels remain stable. When TIE2 signaling decreases or inflammatory stimulation increases, FOXO1 activity can increase and promote ANGPT2 expression, shifting vessels into a more reactive and unstable state.

(3) Research significance

ANGPT2 is not only a ligand in the TIE2 pathway but also a readout of endothelial stress. Increased ANGPT2 often suggests that the endothelium is under inflammatory, hypoxic, or remodeling stress, but it should not be interpreted alone as enhanced angiogenesis.

2.4 VE-cadherin and Barrier Stability

(1) Junction maintenance

ANGPT1-TIE2 signaling can stabilize VE-cadherin-mediated endothelial cell junctions and reduce intercellular gap formation, thereby decreasing vascular permeability.

(2) Rac1 and RhoA balance

ANGPT1 tends to enhance Rac1-related cortical actin structures and inhibit excessive RhoA/ROCK-mediated contractile stress. This balance helps maintain endothelial cell spreading and junction integrity.

(3) Functional endpoints

In endothelial barrier studies, ANGPT1-TIE2 effects should be evaluated using TEER, FITC-dextran permeability, VE-cadherin localization, F-actin stress fibers, and endothelial intercellular gap area.

3、ANGPT2-TIE2 Axis and Vascular Destabilization

3.1 ANGPT2 Release and Endothelial Activation

(1) Rapid release

ANGPT2 is stored in endothelial Weibel-Palade bodies, and inflammatory cytokines, hypoxia, thrombin, VEGF, and vascular injury stimuli can induce its rapid release. Therefore, ANGPT2 is often used to reflect endothelial activation and vascular stress.

(2) Vascular destabilization

ANGPT2 can competitively interfere with stable ANGPT1-mediated TIE2 activation, making endothelial cells more susceptible to VEGF, TNF-α, IL-1β, and mechanical stress. Under this condition, vascular permeability increases, pericyte coverage decreases, and endothelial junctions become loosened.

(3) Context dependence

ANGPT2 is not an absolute TIE2 antagonist. Under different concentrations, cellular environments, and receptor states, ANGPT2 may also show partial agonistic effects. Therefore, ANGPT2 should not be simply written as a fixed “TIE2-inhibiting” factor in experiments.

3.2 ANGPT2 and VEGF Synergy

(1) VEGF-sufficient conditions

In hypoxic tissues or tumor microenvironments with abundant VEGF, ANGPT2 can promote vascular sprouting, endothelial migration, and abnormal neovascularization. In this context, ANGPT2 loosens the vascular wall, while VEGF drives endothelial proliferation and migration.

(2) VEGF-deficient conditions

If VEGF levels are insufficient, ANGPT2-mediated vascular destabilization may cause vascular regression, endothelial cell apoptosis, or vessel withdrawal. This mechanism explains why ANGPT2 can produce opposite outcomes in different diseases and at different stages.

(3) Combined interpretation

In angiogenesis studies, ANGPT2 should be analyzed together with VEGFA, VEGFR2, p-ERK, endothelial proliferation, endothelial migration, and vessel density. Increased ANGPT2 alone cannot determine whether the final vascular outcome is neovascularization, regression, or leakage.

3.3 ANGPT2 and the Inflammatory Microenvironment

(1) Endothelial adhesion molecules

Increased ANGPT2 can promote endothelial inflammatory activation and increase the expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin, thereby enhancing leukocyte adhesion and transendothelial migration.

(2) Vascular leakage

Under inflammatory conditions, ANGPT2 can weaken TIE2-stabilizing signals, making endothelial junctions more vulnerable to disruption by TNF-α, IL-1β, VEGF, and other factors, leading to plasma protein extravasation and tissue edema.

(3) Immune cell interaction

ANGPT2 affects not only endothelial cells but also immune cell entry into tissues by altering vascular permeability, adhesion molecules, and the chemotactic environment. In tumors and chronic inflammation, this process may promote abnormal immune cell accumulation and tissue structural remodeling.

4、Downstream Signals and Cellular Functional Outputs

4.1 PI3K-AKT-FOXO1 Axis

(1) Vascular protective effect

PI3K-AKT is one of the most important protective signals downstream of ANGPT1-TIE2. This axis promotes endothelial survival, inhibits FOXO1 nuclear localization, reduces ANGPT2 transcription, and maintains a low-inflammatory endothelial state.

(2) Consequences of weakened signaling

When TIE2-AKT signaling decreases, FOXO1 more easily enters the nucleus and promotes the expression of ANGPT2, inflammation-related genes, and vascular instability programs. This state is commonly seen in inflammation, hypoxia, tumors, and vascular injury.

(3) Experimental indicators

p-AKT, nuclear/cytoplasmic distribution of FOXO1, ANGPT2 mRNA/protein, endothelial apoptosis, and endothelial barrier function can serve as core readouts of this axis.

4.2 Rho GTPases and the Cytoskeleton

(1) Rac1-related stabilization

ANGPT1-TIE2 usually promotes the formation of Rac1-related cortical actin structures, helping maintain VE-cadherin junctions and stable cell borders.

(2) RhoA/ROCK-related contraction

Under inflammatory or ANGPT2-dominant conditions, enhanced RhoA/ROCK signaling can promote stress fiber formation and endothelial cell contraction, causing enlarged intercellular gaps and increased vascular permeability.

(3) Barrier analysis

Cytoskeleton studies should combine F-actin staining, VE-cadherin immunofluorescence, intercellular gap area, TEER, and permeability assays. Measuring only RhoA or Rac1 expression is not sufficient to determine endothelial barrier status.

4.3 MAPK and Endothelial Migration

(1) ERK signaling

TIE2 signaling can activate ERK under certain conditions and participate in endothelial cell migration, survival, and vascular structural adjustment. When ANGPT2 and VEGF are both present, ERK-related migration and proliferation responses may be enhanced.

(2) p38/JNK signaling

Under inflammatory or stress conditions, p38 and JNK can participate in endothelial inflammatory transcription, cellular stress responses, and vascular injury. Increased ANGPT2 often appears together with these stress pathways.

(3) Mechanistic distinction

If the study focuses on vascular stabilization, more attention should be paid to AKT, FOXO1, VE-cadherin, and barrier function. If the study focuses on angiogenesis or pathological vascular remodeling, ERK, endothelial migration, tube formation, and vessel density analyses should be added.

Table 2 Key Downstream Signals and Detection Indicators of the Angiopoietin-TIE2 Pathway

Signaling axis	Main molecules	Functional output	Recommended detection indicators
TIE2 phosphorylation	p-TIE2/TEK	Receptor activation status	p-TIE2, total TIE2, ANGPT1/ANGPT2 ratio
PI3K-AKT	PI3K, AKT	Endothelial survival and vascular protection	p-AKT, apoptosis, eNOS activity
AKT-FOXO1	AKT, FOXO1	Suppresses ANGPT2 transcription and maintains quiescence	FOXO1 nuclear localization, ANGPT2 mRNA/protein
VE-cadherin junctions	VE-cadherin, β-catenin	Endothelial barrier stability	VE-cadherin localization, TEER, permeability
Rho GTPases	Rac1, RhoA, ROCK	Cytoskeletal and intercellular gap regulation	F-actin, stress fibers, intercellular gaps
MAPK	ERK, p38, JNK	Migration, inflammation, and stress responses	p-ERK, p-p38, endothelial migration
Inflammatory activation	ICAM-1, VCAM-1, E-selectin	Leukocyte adhesion and inflammatory infiltration	Adhesion molecules, leukocyte adhesion assay

5、Angiopoietin-TIE2 Signaling in Pathophysiological Contexts

5.1 Tumor Vessels and the Tumor Microenvironment

(1) Abnormal angiogenesis

In the tumor microenvironment, hypoxia and increased VEGF can induce ANGPT2 expression and shift vessels into a destabilized state. When ANGPT2 acts together with VEGF, it can promote abnormal vascular sprouting, endothelial migration, and disordered vascular structure.

(2) Vascular permeability and hypoxia

Under ANGPT2-dominant conditions, tumor vessels often show high permeability, insufficient pericyte coverage, and uneven perfusion. This vascular structure worsens tissue hypoxia and further stimulates VEGF and ANGPT2 expression, forming a vicious cycle.

(3) TIE2-expressing macrophages

TIE2-expressing macrophages may be present in tumors and participate in angiogenesis, immunosuppression, and tumor invasion. Studies should distinguish endothelial TIE2 signaling from TIE2-expressing immune cell-related effects and avoid interpreting all TIE2-positive signals as endothelial pathway activation.

5.2 Inflammation, Infection, and Vascular Leakage

(1) Inflammatory ANGPT2 release

During infection, sepsis, acute lung injury, and systemic inflammation, endothelial cells can rapidly release ANGPT2, weakening the barrier-protective effect of ANGPT1-TIE2 and making vessels more sensitive to inflammatory factors.

(2) Barrier disruption

Increased ANGPT2 is closely associated with VE-cadherin junction disruption, plasma extravasation, tissue edema, and leukocyte extravasation. Whether TIE2 signaling is inhibited in this context should be determined by p-TIE2, p-AKT, and barrier function assays, not only by ANGPT2 concentration.

(3) Therapeutic research directions

In inflammatory leakage models, enhancing TIE2 signaling, inhibiting ANGPT2, or regulating VE-PTP can all serve as vascular protection strategies. However, inflammatory intensity, VEGF level, and vascular bed type differ across models, so results should be interpreted by tissue context.

5.3 Ocular Vascular Diseases

(1) Retinal angiogenesis

In diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, and other diseases, VEGF and ANGPT2 often participate in abnormal angiogenesis and vascular leakage. ANGPT2 makes vessels more unstable, whereas VEGF drives endothelial proliferation and leakage responses.

(2) Vascular leakage and edema

An ANGPT2-dominant state can weaken TIE2 barrier protection, increase retinal vascular permeability, and promote exudation and edema. Studies of this type should simultaneously focus on vascular leakage, endothelial junctions, inflammatory cell infiltration, and neovascular area.

(3) Significance of combined targeting

In ocular vascular diseases, VEGF inhibition alone can reduce neovascularization and leakage, but abnormalities in the ANGPT2-TIE2 axis may still affect vascular stability. Therefore, combined analysis of VEGF and ANGPT2/TIE2 is more suitable for explaining complex vascular lesions.

5.4 Cardiovascular and Metabolic Vascular Injury

(1) Atherosclerosis

In vascular inflammation and endothelial activation, increased ANGPT2 can promote adhesion molecule expression and immune cell infiltration, participating in the maintenance of an inflammatory plaque environment. ANGPT1-TIE2 signaling is more oriented toward stabilizing the endothelium and reducing inflammatory responses.

(2) Diabetic vascular disease

Hyperglycemia, oxidative stress, and chronic inflammation can disrupt endothelial homeostasis and affect the ANGPT1/ANGPT2 balance. Increased ANGPT2 is often associated with increased microvascular permeability, endothelial dysfunction, and local inflammation.

(3) Tissue ischemia repair

In ischemic tissues, ANGPT2 and VEGF can jointly participate in vascular remodeling. Early vascular destabilization may help neovessel formation, but persistent ANGPT2 elevation may lead to immature vessels and insufficient functional perfusion.

6、Experimental Detection, Product Selection, and Research Design

6.1 Cell Models

(1) Endothelial cell models

HUVECs, HDMECs, HAECs, brain microvascular endothelial cells, and retinal microvascular endothelial cells are commonly used to study ANGPT1/ANGPT2-TIE2 signaling. Endothelial cells of different origins respond differently to ANGPT2, VEGF, inflammatory factors, and shear stress, and should not be compared simplistically.

(2) Pericyte-endothelial co-culture

ANGPT1 is often derived from pericytes and vascular support cells, so endothelial monoculture may underestimate ANGPT1-TIE2 homeostatic signaling. Pericyte-endothelial co-culture or three-dimensional vascular models are more suitable for studying vascular maturation and barrier stability.

(3) Inflammatory and hypoxic stimulation

TNF-α, IL-1β, LPS, hypoxia, VEGF, and thrombin are commonly used to induce ANGPT2 release and endothelial instability. Experiments should include time gradients because ANGPT2 release, decreased TIE2 phosphorylation, and barrier disruption occur in sequence.

6.2 Key Detection Indicators

(1) Pathway activation indicators

p-TIE2, total TIE2, p-AKT, FOXO1 nuclear localization, and ANGPT2 expression are core indicators for judging pathway status. The ANGPT1/ANGPT2 ratio is usually more informative than detecting either ligand alone.

(2) Barrier function indicators

TEER, FITC-dextran permeability, VE-cadherin localization, F-actin structure, and intercellular gap area can reflect endothelial barrier function. In animal models of vascular leakage, Evans blue, fluorescent dextran, or tissue edema indicators can also be used.

(3) Angiogenesis indicators

Endothelial migration, tube formation, EdU/Ki-67 proliferation, vascular sprouting, CD31 vessel density, pericyte coverage, and perfusion function can be used to evaluate angiogenesis and vascular maturation.

6.3 Related Reagent and Tool Selection

Table 3 Reagents and Tools Related to the Angiopoietin-TIE2 Signaling Pathway

Cat. No.	Product Name	Grade/Specification	Product category	Corresponding pathway link	Application positioning
A1496028	AMG-Tie2-1	Moligand™, 10 mM in DMSO	TIE2-related small-molecule tool	TIE2/TEK receptor regulation	Used for TIE2-related pharmacological regulation studies; suitable for analyzing the effects of TIE2 signaling on endothelial stability, migration, or downstream AKT/ERK signaling
Ab209774	Regeneron patent anti-TIE-2 (anti-TIE2)	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	TIE2 antibody/blocking tool	TIE2 receptor detection and functional intervention	Used for TIE2 protein detection, receptor function studies, or TIE2-related blocking experiments; suitable for vascular endothelial and tumor vascular microenvironment research
T1451774	Tie2 kinase inhibitor 3		TIE2 kinase inhibitor	TIE2 receptor tyrosine kinase activity	Used to inhibit TIE2 kinase activity and verify whether TIE2 phosphorylation and downstream AKT/ERK signaling participate in endothelial responses
T407852	Tie2 kinase inhibitor	Moligand™, 10mM in DMSO	TIE2 kinase inhibitor	TIE2 receptor tyrosine kinase activity	Used for pharmacological inhibition of the TIE2 pathway; suitable for mechanistic studies of endothelial barrier, angiogenesis, and vascular permeability
B288179	BAY 826	≥98%(HPLC)	TIE2 inhibitor	TIE2 signaling blockade	Used to inhibit TIE2-related signaling and analyze regulation of endothelial cell function by the ANGPT1/ANGPT2-TIE2 axis
B1493208	BAY-826	Moligand™, 10 mM in DMSO	TIE2 inhibitor	TIE2 signaling blockade	Suitable for TIE2 pharmacological inhibition in cell experiments and observing changes in p-TIE2, p-AKT, endothelial migration, and barrier function
EJ1512660	Mouse TEK Tyrosine Kinase, Endothelial (Tie2) ELISA Kit	BioReagent	ELISA kit	TIE2/TEK expression detection	Used to detect Tie2 levels in mouse samples; suitable for mouse angiogenesis, inflammatory leakage, tumor vascular, and tissue repair models
Ab087899	AKT(phospho S473) Antibody	Validated, ExactAb™, See COA	p-AKT antibody	TIE2 downstream PI3K-AKT signaling	Used to detect AKT S473 phosphorylation after TIE2 activation; an important tool for judging ANGPT1-TIE2 protective signaling
Ab087937	AKT1 Mouse mAb	ExactAb™, Validated, Carrier Free, 1.0mg/mL	AKT1 antibody	AKT total protein detection	Used to detect AKT1 expression and help distinguish changes in total AKT from phosphorylation activation
Ab087925	Recombinant AKT1/AKT2/AKT3 Antibody	Recombinant,ExactAb™,Validated,See COA	pan-AKT antibody	PI3K-AKT downstream pathway	Used to detect total AKT family proteins; suitable for combined interpretation with p-AKT antibodies to assess TIE2-AKT activation
EJ1513410	Human AKT Protein (AKT) ELISA Kit	BioReagent	ELISA kit	AKT total protein detection	Used to detect AKT levels in human-derived samples; suitable for quantitative analysis of ANGPT-TIE2 downstream signaling
EJ1514437	Human Phosphorylated AKT Protein (p-AKT) ELISA Kit	BioReagent	ELISA kit	p-AKT signal detection	Used to detect p-AKT levels in human-derived samples; suitable for evaluating whether ANGPT1-TIE2 activates PI3K-AKT protective signaling
EJ1512454	Mouse AKT Protein (AKT) ELISA Kit	BioReagent	ELISA kit	AKT total protein detection	Used to detect AKT levels in mouse tissue or cell samples; suitable for downstream signal analysis in mouse vascular models
EJ1512962	Mouse Phosphorylated AKT Protein (p-AKT) ELISA Kit	BioReagent	ELISA kit	p-AKT signal detection	Used for quantitative detection of p-AKT in mouse samples; suitable for evaluating downstream signaling changes after Tie2 activation or inhibition
A648039	AKT Kinase Inhibitor	≥99%	AKT inhibitor	PI3K-AKT downstream signaling blockade	Used to verify whether TIE2-mediated endothelial survival, barrier stabilization, or anti-inflammatory effects depend on the AKT pathway
A655267	AKT Kinase Inhibitor	10mM in DMSO	AKT inhibitor	PI3K-AKT downstream signaling blockade	Suitable for blocking AKT signaling in cell experiments and analyzing functional contribution of the ANGPT1-TIE2-AKT axis
A648083	(E)-Akt inhibitor-IV	≥99%	AKT inhibitor	AKT activity inhibition	Used to inhibit AKT activity and validate the role of TIE2 downstream AKT signaling in endothelial barrier and cell survival
A655285	(E)-Akt inhibitor-IV	10mM in DMSO	AKT inhibitor	AKT activity inhibition	Suitable for in vitro cell experiments and direct treatment of endothelial cell models
A1462588	AKT1 Human Pre-designed siRNA Set A		siRNA	AKT1 gene silencing	Used to knock down AKT1 and validate the role of downstream AKT1 of TIE2 in endothelial cell survival, junction stability, and anti-apoptosis
A1485204	Akt1 Mouse Pre-designed siRNA Set A		siRNA	Akt1 gene silencing	Used for Akt1 functional validation in mouse-derived endothelial cells or related models
P659144	PI3K/AKT-IN-1	≥99%	PI3K/AKT pathway inhibitor	PI3K-AKT axis	Used to block TIE2 downstream PI3K-AKT signaling; suitable for mechanistic validation experiments
P661661	PI3K/AKT-IN-1	10mM in DMSO	PI3K/AKT pathway inhibitor	PI3K-AKT axis	Suitable for cell experiments to analyze whether ANGPT1/TIE2-mediated barrier protection depends on PI3K-AKT
P1420619	PI3K/AKT-IN-2	≥98%	PI3K/AKT pathway inhibitor	PI3K-AKT axis	Used for TIE2 downstream signaling blockade and pathway-dependence validation
P1497398	PI3K/AKT-IN-2	Moligand™, 10 mM in DMSO	PI3K/AKT pathway inhibitor	PI3K-AKT axis	Suitable for pharmacological intervention in endothelial cell migration, barrier function, and survival assays
P650618	PI3K/Akt/CREB activator 1	≥99%	PI3K/Akt activator	AKT signal enhancement	Can be used to simulate or enhance AKT-related protective signaling and assist analysis of the role of the TIE2-AKT axis in endothelial homeostasis
P656344	PI3K/Akt/CREB activator 1	10mM in DMSO	PI3K/Akt activator	AKT signal enhancement	Suitable for enhancing PI3K/AKT/CREB signaling in cell experiments and observing whether endothelial barrier or survival status improves
E656204	ERK1/2 inhibitor 1	10mM in DMSO	ERK1/2 inhibitor	TIE2/VEGF-related MAPK signaling	Used to inhibit ERK1/2 signaling and verify whether endothelial migration or angiogenesis under ANGPT2-VEGF conditions depends on ERK
E650276	ERK1/2 inhibitor 1	≥99%	ERK1/2 inhibitor	MAPK-ERK signal blockade	Suitable for studying ERK-dependent angiogenic mechanisms in TIE2/VEGF crosstalk
E651535	ERK1/2 inhibitor 7	≥98%	ERK1/2 inhibitor	MAPK-ERK signal blockade	Used to block ERK1/2 and analyze changes in endothelial migration, proliferation, and tube formation
E1496954	ERK1/2 inhibitor 7	Moligand™, 10 mM in DMSO	ERK1/2 inhibitor	MAPK-ERK signal blockade	Suitable for cellular-level intervention in ANGPT2/VEGF-related ERK signaling
Ab102232	ERK2 Mouse mAb	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA	ERK2 antibody	ERK total protein detection	Used to detect ERK2 expression and assist analysis of whether the MAPK branch participates in TIE2-related endothelial responses
Ab102223	Recombinant ERK1 Antibody	ExactAb™, Validated, Recombinant, High performance, 2mg/mL	ERK1 antibody	ERK total protein detection	Used for ERK1 expression detection; suitable for combination with phosphorylated ERK indicators
Ab326841	Recombinant ERK1/2 Antibody	KD Validation	ERK1/2 antibody	MAPK-ERK pathway detection	Used to detect total ERK1/2 protein and assist analysis of ANGPT2/VEGF-related MAPK signaling
rp184918	Recombinant Human ERK1 Protein	Carrier Free,Bioactive,ActiBioPure™,His Tag,≥85%(SDS-PAGE),See COA	Recombinant ERK1 protein	ERK pathway tool protein	Used for establishing ERK-related experimental systems, antibody validation, or downstream mechanism studies
rp184960	Recombinant Human ERK2 Protein	Carrier Free, Bioactive, ActiBioPure™, ≥90%(SDS-PAGE), See COA	Recombinant ERK2 protein	ERK pathway tool protein	Used for ERK2-related experiments, antibody validation, or MAPK pathway studies
EJ1512223	Rat Extracellular Signal Regulated Kinase 1(ERK1) ELISA Kit	BioReagent	ELISA kit	ERK1 detection	Used to detect ERK1 levels in rat vascular injury, inflammation, or tissue repair models
EJ1513045	Mouse Extracellular Signal Regulated Kinase 1 (ERK1) ELISA Kit	BioReagent	ELISA kit	ERK1 detection	Used to detect ERK1 levels in mouse angiogenesis, inflammatory leakage, or tumor vascular models
V1447346	VEGFR-2/AKT-IN-1		VEGFR-2/AKT crosstalk pathway inhibitor	VEGF-ANGPT/TIE2 crosstalk background	Used to analyze crosstalk regulation between VEGF and TIE2 downstream AKT signaling; suitable for pathological angiogenesis studies
V1418129	VEGFR-2/AKT-IN-2		VEGFR-2/AKT crosstalk pathway inhibitor	VEGF-ANGPT/TIE2 crosstalk background	Suitable for studying mechanisms of endothelial migration, proliferation, and angiogenesis under ANGPT2 and VEGF synergistic conditions

6.4 Common Misconceptions

(1) Equating increased ANGPT2 with enhanced angiogenesis

Increased ANGPT2 only indicates that vessels are unstable or activated. Whether angiogenesis occurs depends on VEGF, inflammatory background, pericyte coverage, and endothelial proliferation status.

(2) Detecting only total TIE2 protein

Total TIE2 protein does not represent pathway activation. TIE2 pathway studies should detect p-TIE2 and downstream signaling together with functional endpoints.

(3) Ignoring cellular sources

ANGPT1 is mostly derived from vascular support cells, ANGPT2 mostly from endothelial cells, and TIE2 can be expressed in both endothelial cells and some immune cells. In tissue samples, source clarification through colocalization or cell sorting is necessary.

Table 4 Experimental Design and Interpretation Points for the Angiopoietin-TIE2 Pathway

Research objective	Recommended detection combination	Interpretation focus
Determine whether TIE2 is activated	p-TIE2, total TIE2, p-AKT, FOXO1 localization	Focus on phosphorylation and downstream signals, not only total protein
Analyze vascular stability	ANGPT1/ANGPT2 ratio, VE-cadherin, TEER, permeability	Focus on endothelial junctions and barrier function
Analyze pathological angiogenesis	ANGPT2, VEGF, CD31, Ki-67, tube formation, pericyte coverage	Distinguish neovessel number from vascular maturity
Analyze inflammatory leakage	ANGPT2, ICAM-1, VCAM-1, VE-cadherin, Evans blue	Evaluate inflammatory activation and vascular barrier disruption
Analyze tumor vessels	ANGPT2, VEGF, TIE2, CD31, α-SMA, markers of TIE2-expressing immune cells	Evaluate both endothelial cells and TIE2-expressing immune cells
Analyze therapeutic intervention	p-TIE2, ANGPT2, vascular permeability, tissue perfusion	Focus on whether pathway restoration translates into functional improvement

The core value of the Angiopoietin-TIE2 signaling pathway lies in explaining the transition of blood vessels from a quiescent and stable state to inflammatory activation, leakage, and pathological remodeling. The ANGPT1-TIE2 axis tends to maintain endothelial barrier integrity, vascular maturation, and anti-inflammatory homeostasis. ANGPT2, in contrast, drives vascular destabilization in hypoxic, inflammatory, and tumor environments, making vessels more sensitive to VEGF and inflammatory signals.

For more related articles, please see below:

[1] Ras-Raf-MEK-ERK Signaling

[2] Wnt/β-Catenin Signaling Pathway

[3] How to Map the NF-κB Pathway and Choose Inhibitors: Bringing Inflammatory Transcriptional Output into a “Controllable Range” (Tables A–F)

[4] Metabolic signaling pathway

[5] Wnt Signaling

[6] Hedgehog Signaling

[7] JAK-STAT Cell Signaling Pathway

[8] PD-1/PD-L1 Signaling Pathway